Nasdaq · Healthcare
Arcutis Biotherapeutics, Inc. (ARQT)
As-reported financials and recent SEC filings for Arcutis Biotherapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$376.1M
Net income
$-16.1M
Net margin
-4.3%
Diluted EPS
$-0.13
ROE
-8.5%
P/E (TTM)
—
Market cap
$3.38B
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M | $0 |
| Gross profit | $339.4M | $177.4M | $54.6M | $2.9M | — |
| Operating income | $-12.2M | $-128.4M | $-241.1M | $-301.6M | $-206.5M |
| Net income | $-16.1M | $-140.0M | $-262.1M | $-311.5M | $-206.4M |
| Diluted EPS | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-17
View on EDGAR →1442026-06-15
View on EDGAR →1442026-06-15
View on EDGAR →4/A2026-06-12
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →Go deeper on ARQT
Search Arcutis Biotherapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.